Chair & Company Secretary
Present Value Ltd
Chair & Company Secretary
Present Value Ltd
Covestus Healthcare Ltd
Dan has worked in Canada, Germany and France and graduated from Brunel University in Applied Biochemistry. In 2011 Dan won the PLG/AstraZeneca BD Executive of the Year award.
52 North Health
... negotiator of multi-million pound pharmaceutical asset transactions
Prior to joining Business Development, Umaima practised as a solicitor. She worked in the legal field for 9 years, primarily as in-house legal counsel within the banking and finance sector including most recently at Citibank and, subsequently, within life sciences at Abcam.
Umaima holds an LLB (Hons) in Law with European Legal Studies from King’s College London and an MPhil in Bioscience Enterprise from the University of Cambridge.
... Prior to joining GSK, Keith worked in various industries including fine & heavy chemical, forestry, music, food, biotech and consultancy as well as 3 business start-ups. He is also a professional touring musician. [More]
... than 30 years experience in international pharmaceutical business development.
Sharon’s previous industry experience includes senior business development appointments in the Wellcome Foundation Ltd (Wellcome Research and Wellcome Diagnostics); at Medeva plc and Ono Pharmaceutical Co. Ltd. In addition to her client work, Sharon is the Editor of the Business Development & Licensing Journal published by the Pharmaceutical Licensing Group and is also the Course Director for the MSc in Pharmaceutical Business Development and Licensing run by Manchester University.
Sharon holds a BSc in Chemistry and Administration and studied for an MA in Business Law. Sharon has worked in a wide range of therapeutic fields including diabetes, oncology, respiratory, critical care, cardiovascular and diagnostics. She is a past President of the European Pharmaceutical Licensing Group Council and former Chairman of the UK Pharmaceutical Licensing Group.
... is a Phase 2 respiratory syncytial virus (RSV) fusion inhibitor.
Previously, Cora worked at the Finnish drug delivery and drug development company DelSiTech Ltd. The Company's lead internal programme is a long acting hepatitis B (HBV) product. Prior to DelSiTech, Cora had business development roles at the drug delivery company Q Chip and the AstraZeneca (AZ) subsidiary company Arrow Therapeutics. Cora obtained her PhD in Virology at the College of Medicine, Cardiff University and held a postdoctoral position at University College London.
Johnson & Johnson Innovation
... at The Institiute of Cancer Research for over ten years, leading all aspects of projects including the review, protection and exploitation of intellectual property generated by many different research teams. This required the negotiation of numerous agreements with other academic organisations, charity funders, pharmaceutical and biotechnology companies in many different territories. These were typically been to enable major drug discovery and development collaborations.
Toby has also worked on secondment within AstraZeneca’s oncology strategic partnering and business development team. As well as a PhD in oncology Toby holds a first class double honours degree in biochemistry and chemistry.
... technology sectors on a broad range of matters, including licensing and other complex commercial and intellectual property arrangements, as well as UK and European Union Regulatory and data privacy matters related to those transactions.
She provides pragmatic, commercially driven, and digestible advice to help clients achieve their business objectives and strategic goals.
Frances frequently writes and speaks on topics related to legal issues in the life sciences sector, including for publications such as Law360 and Privacy Laws & Business. [More]
... Operations team. Kay is involved in all aspects of transaction negotiation and execution across multiple therapy areas. Prior to that, Kay worked as a Business Development Director covering both search and evaluation, as well as transaction, for AstraZeneca’s Oncology business.
Kay has a wealth of business development experience ranging from in and out-licensing, acquisition and partnering activities from early stage discovery through to on-market commercial opportunities. Before her business development career, Kay worked in R&D at AstraZeneca. She also holds a Ph.D. in molecular biology and a first class honours degree both from the University Manchester.
... and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.
Adrian has a wealth of experience in handling the IP aspects of University spin-outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat-panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.
Adrian publishes and speaks regularly on a variety of intellectual property issues. [More]
Wilson BioPharma Consulting
... years, the last 25 of which were at AstraZeneca where he held several senior business development positions. Campbell has experience of all aspects of business development but his main focus has been on transactions where he has completed over 50 deals.
Campbell has a BSc in pharmacology from Edinburgh University and a PhD in cardiovascular pharmacology from the University of Wales. He was formerly with Beecham Pharmaceuticals (now GSK) before joining ICI Pharmaceuticals (now AstraZeneca) in 1989. He took up his first business development role in 1996.
Campbell has been an independent business development consultant (Wilson BioPharma Consulting) since early 2014. He is also part of Medius Associates and is a non-executive director of Frontier IP. [More]